697 related articles for article (PubMed ID: 31628431)
1. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
Jonas BA; Pollyea DA
Leukemia; 2019 Dec; 33(12):2795-2804. PubMed ID: 31628431
[TBL] [Abstract][Full Text] [Related]
2. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
3. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
4. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
5. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
[TBL] [Abstract][Full Text] [Related]
6. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
8. New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S; Eskazan AE
Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
[TBL] [Abstract][Full Text] [Related]
9. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
Mei M; Aldoss I; Marcucci G; Pullarkat V
Am J Hematol; 2019 Mar; 94(3):358-362. PubMed ID: 30499168
[TBL] [Abstract][Full Text] [Related]
10. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Huemer F; Melchardt T; Jansko B; Wahida A; Jilg S; Jost PJ; Klieser E; Steiger K; Magnes T; Pleyer L; Greil-Ressler S; Rass C; Greil R; Egle A
Eur J Haematol; 2019 May; 102(5):437-441. PubMed ID: 30725494
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
He H; Wen X; Zheng H
Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylating agents and venetoclax in acute myeloid leukemia.
DiNardo CD
Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
[No Abstract] [Full Text] [Related]
13. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Richardson DR; Green SD; Foster MC; Zeidner JF
Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
16. Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
Diao S; Nichols ED; DiNardo C; Konopleva M; Ning J; Qiao W; Maiti A; DiPippo AJ
Am J Hematol; 2021 Mar; 96(3):E65-E68. PubMed ID: 33259075
[No Abstract] [Full Text] [Related]
17. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
18. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
[TBL] [Abstract][Full Text] [Related]
19. Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
Shahswar R; Beutel G; Gabdoulline R; Koenecke C; Markel D; Eder M; Stadler M; Gohring G; Schlegelberger B; Trummer A; Krauter J; Thol F; Heuser M
Ann Hematol; 2021 Feb; 100(2):595-599. PubMed ID: 32705308
[No Abstract] [Full Text] [Related]
20. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
